Li Ping

Spesialisasi: Hematologist
26 tahun pengalaman
Berbahasa:
Chinese
Tempat kerja: China, Xangai, Tongji Hospital - International Department
Recognized pioneer in China for full-cycle CAR-T therapy for relapsed or refractory blood cancers; leads national and international clinical trials.
Dr. Li Ping, M.D., Ph.D., is Chief Physician and Professor in the Department of Hematology at Shanghai Tongji Hospital, Tongji University School of Medicine. She supervises doctoral and master's students and is an expert in hematologic malignancies.

She earned a Doctor of Medical Science from Nagoya University and completed postdoctoral research. She specializes in diagnosing and treating blood cancers. Her focus includes lymphoid malignancies—leukemias, lymphomas, and multiple myeloma. She treats patients with chemotherapy, hematopoietic stem cell transplantation, targeted therapy, and immunotherapy.

She is a pioneer in China in full-cycle CAR-T therapy for relapsed or refractory blood cancers. She leads and participates in national and international clinical trials. She serves on committees of professional societies, including the China Anti-Cancer Association. She also publishes and trains hematologists.

Layanan dokter

Lihat lagi

Bagaimana pelayanan kami?

1 dari 3

Informasi tentang dokter ini lengkap dan jelas.

Sangat tidak setuju

Sangat setuju

Kualifikasi

Dr. Li Ping, M.D., Ph.D., is a distinguished Chief Physician and Professor in the Department of Hematology at Shanghai Tongji Hospital (Tongji University School of Medicine). As a doctoral and master's supervisor, she is a leading expert in the field of hematologic malignancies, with a distinguished career dedicated to clinical practice, research, and education.

She earned her Doctor of Medical Science degree from the prestigious Nagoya University in Japan, where she also completed advanced postdoctoral research. Dr. Li specializes in the comprehensive diagnosis and treatment of various blood cancers, with a profound focus on lymphoid malignancies, including leukemias, lymphomas, and multiple myeloma. Her clinical expertise spans the entire spectrum of modern hematologic oncology, from conventional chemotherapy and hematopoietic stem cell transplantation to cutting-edge targeted therapies and pioneering immunotherapies.

A recognized pioneer in China, Dr. Li possesses exceptional skill in the full-cycle management of CAR-T (Chimeric Antigen Receptor T-cell) therapy, a revolutionary treatment for relapsed or refractory blood cancers. She actively leads and participates in numerous national and international clinical trials, bringing the most advanced therapeutic options to her patients. In addition to her clinical work, Dr. Li holds significant academic roles, serving as a committee member in several national professional societies, such as the China Anti-Cancer Association. She continues to contribute to scientific literature and guides the next generation of hematologists. Dr. Li is highly respected for her deep clinical acumen, commitment to innovative research, and dedicated, patient-centered care.